vs
Cytek Biosciences, Inc.（CTKB）与因美纳（ILMN）财务数据对比。点击上方公司名可切换其他公司
因美纳的季度营收约是Cytek Biosciences, Inc.的17.8倍（$1.1B vs $62.1M）。因美纳净利率更高（16.8% vs -70.9%，领先87.8%）。Cytek Biosciences, Inc.同比增速更快（8.1% vs -1.6%）。因美纳自由现金流更多（$335.0M vs $-1.8M）。过去两年Cytek Biosciences, Inc.的营收复合增速更高（17.7% vs 0.8%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
CTKB vs ILMN — 直观对比
营收规模更大
ILMN
是对方的17.8倍
$62.1M
营收增速更快
CTKB
高出9.7%
-1.6%
净利率更高
ILMN
高出87.8%
-70.9%
自由现金流更多
ILMN
多$336.8M
$-1.8M
两年增速更快
CTKB
近两年复合增速
0.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $1.1B |
| 净利润 | $-44.1M | $186.0M |
| 毛利率 | 52.9% | 65.9% |
| 营业利润率 | -9.0% | 15.8% |
| 净利率 | -70.9% | 16.8% |
| 营收同比 | 8.1% | -1.6% |
| 净利润同比 | -557.1% | 205.7% |
| 每股收益（稀释后） | — | $1.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBILMN
| Q4 25 | $62.1M | — | ||
| Q3 25 | $52.3M | — | ||
| Q2 25 | $45.6M | — | ||
| Q1 25 | $41.5M | — | ||
| Q4 24 | $57.5M | $1.1B | ||
| Q3 24 | $51.5M | $1.1B | ||
| Q2 24 | $46.6M | $1.1B | ||
| Q1 24 | $44.9M | $1.1B |
净利润CTKBILMN
| Q4 25 | $-44.1M | — | ||
| Q3 25 | $-5.5M | — | ||
| Q2 25 | $-5.6M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q4 24 | $9.6M | $186.0M | ||
| Q3 24 | $941.0K | $705.0M | ||
| Q2 24 | $-10.4M | $-2.0B | ||
| Q1 24 | $-6.2M | $-126.0M |
毛利率CTKBILMN
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | 65.9% | ||
| Q3 24 | 56.3% | 69.0% | ||
| Q2 24 | 54.6% | 64.8% | ||
| Q1 24 | 51.3% | 62.0% |
营业利润率CTKBILMN
| Q4 25 | -9.0% | — | ||
| Q3 25 | -17.6% | — | ||
| Q2 25 | -23.3% | — | ||
| Q1 25 | -36.1% | — | ||
| Q4 24 | 5.2% | 15.8% | ||
| Q3 24 | -8.2% | 68.6% | ||
| Q2 24 | -18.3% | -147.2% | ||
| Q1 24 | -23.9% | -10.3% |
净利率CTKBILMN
| Q4 25 | -70.9% | — | ||
| Q3 25 | -10.5% | — | ||
| Q2 25 | -12.2% | — | ||
| Q1 25 | -27.5% | — | ||
| Q4 24 | 16.8% | 16.8% | ||
| Q3 24 | 1.8% | 65.3% | ||
| Q2 24 | -22.4% | -178.8% | ||
| Q1 24 | -13.8% | -11.7% |
每股收益（稀释后）CTKBILMN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.16 | ||
| Q3 24 | — | $4.42 | ||
| Q2 24 | — | $-12.48 | ||
| Q1 24 | — | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | $93.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $341.7M | $2.4B |
| 总资产 | $461.5M | $6.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTKBILMN
| Q4 25 | $90.9M | — | ||
| Q3 25 | $93.3M | — | ||
| Q2 25 | $75.5M | — | ||
| Q1 25 | $95.3M | — | ||
| Q4 24 | $98.7M | $93.0M | ||
| Q3 24 | $162.3M | $70.0M | ||
| Q2 24 | $177.9M | $74.0M | ||
| Q1 24 | $168.8M | — |
股东权益CTKBILMN
| Q4 25 | $341.7M | — | ||
| Q3 25 | $378.6M | — | ||
| Q2 25 | $377.6M | — | ||
| Q1 25 | $379.6M | — | ||
| Q4 24 | $395.7M | $2.4B | ||
| Q3 24 | $385.5M | $2.1B | ||
| Q2 24 | $389.1M | $1.4B | ||
| Q1 24 | $392.6M | $5.7B |
总资产CTKBILMN
| Q4 25 | $461.5M | — | ||
| Q3 25 | $494.9M | — | ||
| Q2 25 | $493.3M | — | ||
| Q1 25 | $482.6M | — | ||
| Q4 24 | $499.5M | $6.3B | ||
| Q3 24 | $491.2M | $6.0B | ||
| Q2 24 | $483.7M | $6.1B | ||
| Q1 24 | $492.1M | $10.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | $364.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $335.0M |
| 自由现金流率自由现金流/营收 | -2.9% | 30.3% |
| 资本支出强度资本支出/营收 | 1.6% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.96× |
| 过去12个月自由现金流最近4个季度 | $-8.8M | $709.0M |
8季度趋势，按日历期对齐
经营现金流CTKBILMN
| Q4 25 | $-771.0K | — | ||
| Q3 25 | $-3.9M | — | ||
| Q2 25 | $108.0K | — | ||
| Q1 25 | $-125.0K | — | ||
| Q4 24 | $2.0M | $364.0M | ||
| Q3 24 | $13.2M | $316.0M | ||
| Q2 24 | $6.2M | $80.0M | ||
| Q1 24 | $4.0M | $77.0M |
自由现金流CTKBILMN
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | $335.0M | ||
| Q3 24 | $12.2M | $284.0M | ||
| Q2 24 | $5.2M | $49.0M | ||
| Q1 24 | $3.4M | $41.0M |
自由现金流率CTKBILMN
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | 30.3% | ||
| Q3 24 | 23.7% | 26.3% | ||
| Q2 24 | 11.0% | 4.4% | ||
| Q1 24 | 7.6% | 3.8% |
资本支出强度CTKBILMN
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | 2.6% | ||
| Q3 24 | 2.0% | 3.0% | ||
| Q2 24 | 2.3% | 2.8% | ||
| Q1 24 | 1.3% | 3.3% |
现金转化率CTKBILMN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 1.96× | ||
| Q3 24 | 14.05× | 0.45× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
ILMN
| Sequencing | $1.0B | 91% |
| Microarray | $101.0M | 9% |
| Investee | $7.0M | 1% |
